Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC
Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.
EP: 1.The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
EP: 2.Approved Treatment Options for Patients with mCRPC
EP: 3.Patient Profile: A 78-Year-Old Man with mCRPC
EP: 4.Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy
EP: 5.Patient Profile: A 72-Year-Old Man with mCRPC and Multiple Bone Metastases
EP: 6.Safety and Efficacy Data on Radium-223 for the Palliative Treatment of mCRPC
EP: 7.Considerations for Treatment Selection for Patients with Disease Progression on Radium-223
EP: 8.Patient Profile: A 67-Year-Old Man with mCRPC and Asymptomatic Bone Metastases
Now Viewing
EP: 9.Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC
EP: 10.Closing Thoughts on the Future of mCRPC Treatment
Related Videos
Related Content
